Wyzwania związane z leczeniem zakażenia Helicobacter pylori: co nowego po Maastricht VI? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
paź 20, 2026
Słowa kluczowe:
eradykacja, Helicobacter pylori, probiotyki
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule przedstawiono przegląd aktualnych doniesień dotyczących eradykacji Helicobacter pylori, a także zasad stosowania probiotyków w celu poprawy skuteczności leczenia i zmniejszenia ryzyka wystąpienia działań niepożądanych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gąsiorowska, A. (2026). Wyzwania związane z leczeniem zakażenia Helicobacter pylori: co nowego po Maastricht VI?. Medycyna Faktów , 19(2(71), 170-173. https://doi.org/10.24292/01.MF.0226.4
Numer
Dział
Artykuły
Copyright by Medical Education. All rights reserved.
Bibliografia
1. Malfertheiner P, Megraud P, Rokkas T et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022; 71: 1724-62.
2. Jaroń K, Pietrzak A, Daniluk J et al. Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the Working Group of the Polish Society of Gastroenterology. Gastroenterology Rev. 2023; 18(3): 225-48.
3. Olmedo L, Calvet X, Gene E et al. Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg). Gut. 2024; 74(1): 15-25.
4. Nyssen OP, Montes N, Perez-Aisa A et al. Effectiveness and Safety of First-Line Non-Bismuth Quadruple Concomitant Therapy Versus Single- Capsule Bismuth Quadruple Therapy. Aliment Pharmacol Therap. 2025; 62: 809-20.
5. Martinez-Domingues SJ, Lanas A, Ceamanos E et al. Higher Doses of Bismuth and Antibiotics Do Not Improve Helicobacter pylori Treatment Effectiveness: Results From European Registry on Helicobacter pylori Management. Clin Gastroenterol Hepatol. 2026; 0.
6. Yuan L, Yang C, Han Y et al. Beyond antibiotics: probiotics as a promising ally against Helicobacter pylori. Front Pharmacol. 2025; 16: 1620870.
7. Deza DC, Alcedo J, Lafuente M et al. Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg). Am J Gastroenterol. 2025; 120: 2644-59.
8. Nyssen OP, Jonaitis L, Perez-Aisa A et al. Real-World Effectiveness and Safety of Saccharomyces boulardii CNCM I-745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp- EuReg). Helicobacter. 2026; 31: e70119.
9. Yang Z, Zhou Y, Han Z et al. The effects of probiotics supplementation on Helicobacter pylori standard treatment: an umbrella review of systematic reviews with meta analyses. Sci Rep. 2024; 14: 10069.
10. Banasiewicz T, Domagalska D, Borycka-Kiciak K et al. Determination of butyric acid dosage based on clinical and experimental studies – a literature review. Gastroenterology Rev. 2020; 15(2): 119-25.
2. Jaroń K, Pietrzak A, Daniluk J et al. Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the Working Group of the Polish Society of Gastroenterology. Gastroenterology Rev. 2023; 18(3): 225-48.
3. Olmedo L, Calvet X, Gene E et al. Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg). Gut. 2024; 74(1): 15-25.
4. Nyssen OP, Montes N, Perez-Aisa A et al. Effectiveness and Safety of First-Line Non-Bismuth Quadruple Concomitant Therapy Versus Single- Capsule Bismuth Quadruple Therapy. Aliment Pharmacol Therap. 2025; 62: 809-20.
5. Martinez-Domingues SJ, Lanas A, Ceamanos E et al. Higher Doses of Bismuth and Antibiotics Do Not Improve Helicobacter pylori Treatment Effectiveness: Results From European Registry on Helicobacter pylori Management. Clin Gastroenterol Hepatol. 2026; 0.
6. Yuan L, Yang C, Han Y et al. Beyond antibiotics: probiotics as a promising ally against Helicobacter pylori. Front Pharmacol. 2025; 16: 1620870.
7. Deza DC, Alcedo J, Lafuente M et al. Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg). Am J Gastroenterol. 2025; 120: 2644-59.
8. Nyssen OP, Jonaitis L, Perez-Aisa A et al. Real-World Effectiveness and Safety of Saccharomyces boulardii CNCM I-745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp- EuReg). Helicobacter. 2026; 31: e70119.
9. Yang Z, Zhou Y, Han Z et al. The effects of probiotics supplementation on Helicobacter pylori standard treatment: an umbrella review of systematic reviews with meta analyses. Sci Rep. 2024; 14: 10069.
10. Banasiewicz T, Domagalska D, Borycka-Kiciak K et al. Determination of butyric acid dosage based on clinical and experimental studies – a literature review. Gastroenterology Rev. 2020; 15(2): 119-25.